BURLINGTON, Mass. (AP) _ Flexion Therapeutics Inc. (FLXN) on Tuesday reported a loss of $43.9 million in its second quarter.

On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of $1.16.

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.22 per share.

The specialty pharmaceutical companies that specializes in pain relief posted revenue of $3.8 million in the period, which did not meet Street forecasts. Four analysts surveyed by Zacks expected $4 million.

Flexion Therapeutics shares have fallen almost 9 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $22.82, a climb of almost 3 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FLXN at https://www.zacks.com/ap/FLXN